Enzon Pharmaceuticals Surges Post-Klarman Sale

Enzon Pharmaceuticals Surges Post-Klarman Sale

Today’s midday gainers are Enzon Pharmaceuticals Inc (NASDAQ:ENZN), Gilead Sciences, Inc. (NASDAQ:GILD) and Sirius XM Holdings Inc. (NASDAQ:SIRI). J.C. Penney Company, Inc. (NYSE:JCP), MakeMyTrip Limited (NASDAQ:MMYT) and Kindred Biosciences Inc (NASDAQ:KIN) are the losers.

Play Quizzes 4

Enzon Pharmaceuticals Surges

Enzon Pharmaceuticals Inc (NASDAQ:ENZN) surged +4.77% midday today, rendering it this Friday’s top midday gainer. The Carl Icahn holding used to be also part of Seth Klarman’s portfolio, but it was announced yesterday that he was closing his position in the biotech company.

Maverick Capital Slides 22.9% In Q1, Short Bets Yield Positive Returns [Exclusive]

investor 1652197064Maverick Capital's flagship hedge fund lost -22.9% in the first quarter of 2022 according to a copy of the firm's quarterly update, which ValueWalk has been able to review. The firm's flagship fund, Maverick Fundamental Hedge, accounts for $3.7 billion of the group's $8.1 billion of assets under management. Even after losses in the first Read More

Gilead Sciences, Inc. (NASDAQ:GILD) rebounded +4.34% after a steep fall yesterday. The firm announced new data on drug studies, which will likely help its product offering in the long-run. Tiger Global, Daniel Loeb and Ray Dalio have positions in Gilead.

And on the heels of good news about its senior notes, Sirius XM Holdings is up +4.19%. The satellite radio company is part of Leon Cooperman’s fund.

J.C. Penney is Back in the Red

After performing quite well over the past month, J.C. Penney Company, Inc. (NYSE:JCP) took a dive, its price falling -8.33%. JCP shares have failed to break resistances some time now. The retailer is a George Soros pick.

Tiger Global bet MakeMyTrip Limited (NASDAQ:MMYT), an online provider of travel services in India, posting a -6.09% decline this Friday. The stock is still up +23.36% YTD.

Klarman biotech stock Kindred Biosciences Inc (NASDAQ:KIN) fell -4.69%. This is the second consecutive day the company makes our list of losers – the result of analyst downgrades. Farallon Capital Management has a position in Kindred.

Updated on

No posts to display